© 2014 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. Funded by Scottish Health Informatics Programme. Grant Number: WT086113 Scottish Government Scottish Diabetes Research NetworkPeer reviewedPublisher PD

Abookire

Ashworth

Beard

Bertoni

Boden

Colhoun

Collins

Connolly

Deedwania

DeWilde

Dixon

Gnavi

Hart

Jackson

Joint British Societies

MacBride-Stewart

McKnight

Network

Ohlsson

Selmer

Serruys

Shepherd

Simpson

Thomsen

Tunstall-Pedoe

Wild

English

PubMed

N. R. V. Jones

C. M. Fischbacher

B. Guthrie

G. Leese

R. S. Lindsay

J. A. McKnight

D. Pearson

S. Philip

N. Sattar

S. H. Wild

null null

Crossref

Diabetic Medicine

Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008

Aim: To describe characteristics associated with statin prescribing for the primary prevention of cardiovascular disease in people with newly diagnosed diabetes. Methods: Data from the Scottish Care Information-Diabetes Collaboration data set for 2006-2008 were used. This data set contains socio-demographic and prescribing data for over 99% of people with diagnosed diabetes in Scotland. Analyses were conducted on people aged over 40 years diagnosed with Type 1 or Type 2 diabetes between 2006 and 2008 with complete data and no previous history of cardiovascular or statin prescription. Logistic regression was used to calculate odds ratios for statin prescription in the 2 years following diagnosis of diabetes. Results: There were 7157 men and 5601 women who met the inclusion criteria, 68% of whom had a statin prescription recorded in the 2 years following diagnosis of diabetes. The proportions receiving statins were lower above 65 years of age in men and 75 years of age in women. People with Type 1 diabetes had lower odds of receiving statins than people with Type 2 diabetes [odds ratio (95% CI) 0.42 (0.29-0.61) for men and 0.48 (0.28-0.81) for women, after adjustment for age, BMI, smoking status, cholesterol level and deprivation]. Higher total cholesterol, BMI and being a current smoker were associated with greater odds of statin prescription. Conclusion: Approximately one third of the study population had no record of statin prescription during the 2 years after diagnosis of diabetes. Cardiovascular disease risk reduction opportunities may be missed in some of these people

Jones, N. R. V.

Fischbacher, C. M.

Guthrie, B.

Leese, G.

Lindsay, R. S.

McKnight, J. A.

Pearson, D.

Philip, S.

Sattar, N.

Wild, S. H.

Discovery Research Portal

Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008

To describe characteristics associated with statin prescribing for the primary prevention of cardiovascular disease in people with newly diagnosed diabetes.MethodsData from the Scottish Care InformationDiabetes Collaboration data set for 2006-2008 were used. This data set contains socio-demographic and prescribing data for over 99% of people with diagnosed diabetes in Scotland. Analyses were conducted on people aged over 40years diagnosed with Type1 or Type2 diabetes between 2006 and 2008 with complete data and no previous history of cardiovascular or statin prescription. Logistic regression was used to calculate odds ratios for statin prescription in the 2years following diagnosis of diabetes.ResultsThere were 7157 men and 5601 women who met the inclusion criteria, 68% of whom had a statin prescription recorded in the 2years following diagnosis of diabetes. The proportions receiving statins were lower above 65years of age in men and 75years of age in women. People with Type1 diabetes had lower odds of receiving statins than people with Type2 diabetes [odds ratio (95%CI) 0.42 (0.29-0.61) for men and 0.48 (0.28-0.81) for women, after adjustment for age, BMI, smoking status, cholesterol level and deprivation]. Higher total cholesterol, BMI and being a current smoker were associated with greater odds of statin prescription.ConclusionApproximately one third of the study population had no record of statin prescription during the 2years after diagnosis of diabetes. Cardiovascular disease risk reduction opportunities may be missed in some of these people.What's new?This article reports the first use of Scottish Care Information - Diabetes Collaboration project data to examine which factors are associated with statin prescription in people during the first 2years after diagnosis with diabetes in Scotland. The results suggest that guidelines for the universal use of statins among people with diabetes were not being followed during the study period and that, as a result, opportunities to reduce cardiovascular disease risk were missed. Decision support systems that prompt clinicians of risk reduction strategies could improve adherence to guidelines

Jones, N R V

Fischbacher, C M

Guthrie, B

Leese, G

Lindsay, R S

McKnight, J A

Pearson, D

Philip, S

Sattar, N

Wild, S H

Edinburgh Research Explorer

ª 2014 The Authors. Diabetic Medicine ª

Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia

Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment. Circ Cardiovasc Qual Outcomes

By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart

Diabetes and cardiovascular disease.

Diabetes prevalence and socioeconomic status: a population-based study showing increased prevalence of type 2 diabetes mellitus in deprived areas.

Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Fam Pract

Does general practice reduce health inequalities? Analysis of quality and outcomes framework data.

Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation

Evidence for inequalities in the management of coronary heart disease in

Evolution of statin prescribing 1994–2001: a case of agism but not of sexism? Heart

Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study. Diabet Med

Implementing a national quality assurance system for diabetes care: the Scottish Diabetes Survey 2001–2006. Diabet Med

Is the physician’s adherence to prescription guidelines associated with the patient’s socio-economic position? An analysis of statin prescription in South Sweden.

Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet

Optimal medical therapy with or without PCI for stable coronary disease.

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet

Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner ‘Quality and Outcomes Framework’. J Public Health (Oxf)

Societies. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice.

Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study.

Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education.

Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities.

The care gap: underuse of statin therapy in the elderly.

The inverse care law. Lancet

The Scottish Government. SIMD Methodology. Edinburgh: The Scottish Government,

Use and monitoring of ‘statin’ lipid-lowering drugs compared with guidelines. Arch Intern Med

ª 2014 The Authors. Diabetic Medicine published by

Services Division, NHS National Services Scotland, Edinburgh, Aberdeen UK, 3Quality, Safety and Informatics Research Group, University of Dundee, Aberdeen, UK, 4Diabetes and Endocrinology Department, Ninewells Hospital,

Aim

To describe characteristics associated with statin prescribing for the primary prevention of cardiovascular disease in people with newly diagnosed diabetes.&lt;p&gt;&lt;/p&gt;



Methods

Data from the Scottish Care Information—Diabetes Collaboration data set for 2006–2008 were used. This data set contains socio-demographic and prescribing data for over 99% of people with diagnosed diabetes in Scotland. Analyses were conducted on people aged over 40 years diagnosed with Type 1 or Type 2 diabetes between 2006 and 2008 with complete data and no previous history of cardiovascular or statin prescription. Logistic regression was used to calculate odds ratios for statin prescription in the 2 years following diagnosis of diabetes.&lt;p&gt;&lt;/p&gt;



Results

There were 7157 men and 5601 women who met the inclusion criteria, 68% of whom had a statin prescription recorded in the 2 years following diagnosis of diabetes. The proportions receiving statins were lower above 65 years of age in men and 75 years of age in women. People with Type 1 diabetes had lower odds of receiving statins than people with Type 2 diabetes [odds ratio (95% CI) 0.42 (0.29–0.61) for men and 0.48 (0.28–0.81) for women, after adjustment for age, BMI, smoking status, cholesterol level and deprivation]. Higher total cholesterol, BMI and being a current smoker were associated with greater odds of statin prescription.&lt;p&gt;&lt;/p&gt;



Conclusion

Approximately one third of the study population had no record of statin prescription during the 2 years after diagnosis of diabetes. Cardiovascular disease risk reduction opportunities may be missed in some of these people.&lt;p&gt;&lt;/p&gt

Jones, N.R.V.

Fischbacher, C.M.

Lindsay, R.S

McKnight, J.A.

Wild, S.H.

Enlighten: Publications

Enlighten

© 2014 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. Funded by Scottish Health Informatics Programme. Grant Number: WT086113 Scottish Government Scottish Diabetes Research NetworkPeer reviewe

Scottish Diabetes Research Network (SDRN) Epidemiology group

Aberdeen University Research

http://discovery.dundee.ac.uk/portal/en/research/factors-associated-with-statin-treatment-for-the-primary-prevention-of-cardiovascular-disease-in-people-within-2-years-following-diagnosis-of-diabetes-in-scotland-20062008(628b5fe0-4e8d-4980-a4f7-84778a5ff4ee).html

Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008

Abstract

Similar works

Full text

Available Versions

Crossref

Discovery Research Portal

Edinburgh Research Explorer

Discovery Research Portal

Enlighten: Publications

Discovery Research Portal

Enlighten

Aberdeen University Research

Edinburgh Research Explorer